A new study dampens glutamine enthusiasm

Topics: Antipsychotics

More evidence that antipsychotics are dangerous in dementia

Topics: Antipsychotics

Latest CATIE results: Atypicals no better than Trilafon for improving cognition

Topics: Antipsychotics

Agitation and Depression in Older Patients

Topics: Antipsychotics | Dementia | Depressive Disorder

The molecular mechanism of antipsychotic- induced weight gain is found

Topics: Antipsychotics

Invega: Can You Say "Patent Extender?"

Topics: Antipsychotics

Janssen’s marketing team apparently missed the fact that the word in the English language that sounds most like “Invega” is “inveigle,” meaning “to entice, lure, or ensnare by flattery or artful talk or inducements” (www.dictionary.com). You may have already heard some “artful talk” from your Janssen reps, who are keen to have you conv

Do Second-Generation Antipsychotics Treat Depression? An Update

Topics: Antipsychotics

By Shalom Feinberg, M.D. Associate Clinical Professor of Psychiatry, Albert Einstein College of Medicine A lot has happened in the four years since TCPR first looked at the role of second-generation antipsychotics (SGAs) in the treatment of depression (TCPR, Feb. 2003). The literature has mushroomed, and recently the FDA approved Seroquel (quetiapin

Choosing the Right Antipsychotic

Topics: Antipsychotics

Seroquel vs. Depakote for Impulsivity and Aggression in Teens

Topics: Antipsychotics | Mood Stabilizers

Metformin for Antipsychotic-Induced Weight Gain in Adolescents

Topics: Antipsychotics

Conventionals: Not only cheaper than atypicals, but more effective?

Topics: Antipsychotics

Should We Still use Atypicals for Alzheimer’s Disease?

Topics: Antipsychotics

The CATIE Trial: The Story is in the Dosing

Topics: Antipsychotics

Few clinical trials have ever generated as much buzz as the series of trials known as CATIE. CATIE stands for “Clinical Antipsychotic Trials of Intervention Effectiveness,” and is the only set of trials ever done comparing the major second-generation antipsychotics. And because CATIE is funded entirely by NIMH, its results are thought to be quite tr

Typical Antipsychotics: A Brief Review

Topics: Antipsychotics

Those of us who completed residency anytime during the last 10 years were indoctrinated against the use of conventional neuroleptics because of their array of side effects, particularly extrapyramidal syndromes (EPS) and tardive dyskinesia (TD). This was good education, as long as the atypicals continued to maintain their promise of being more effect

Background of the CATIE Trial

Topics: Antipsychotics

What is an “atypical”?

Topics: Antipsychotics

Following the introduction of the first neuroleptics in the 1950s, pharmaceutical companies continued screening compounds for psychoactive properties. In 1959, at Wander Laboratories (ultimately purchased by Sandoz), researchers were surprised to discover a chemical similar to tricyclic antidepressants that had antipsychotic properties. They named it cl